Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
3.090
-0.230 (-6.93%)
At close: May 30, 2025, 4:00 PM
3.169
+0.079 (2.56%)
After-hours: May 30, 2025, 7:49 PM EDT

Company Description

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.

In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers.

Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation
Omeros logo
Country United States
Founded 1994
IPO Date Oct 8, 2009
Industry Biotechnology
Sector Healthcare
Employees 202
CEO Gregory Demopulos

Contact Details

Address:
The Omeros Building, 201 Elliott Avenue West
Seattle, Washington 98119
United States
Phone 206 676 5000
Website omeros.com

Stock Details

Ticker Symbol OMER
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001285819
CUSIP Number 682143102
ISIN Number US6821431029
Employer ID 91-1663741
SIC Code 2834

Key Executives

Name Position
Dr. Gregory A. Demopulos M.D. Co-Founder, Chairman, Chief Executive Officer and President
David J. Borges Vice President of Finance, Chief Accounting Officer and Treasurer
Peter B. Cancelmo J.D. Vice President, General Counsel and Corporate Secretary
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder
Dr. George A. Gaitanaris M.D., Ph.D. Chief Scientific Officer and Vice President of Science
Peter W. Williams Vice President of Human Resources
Dr. Catherine A. Melfi Ph.D. Chief Regulatory Officer and Vice President of Regulatory Affairs and Quality Systems
Nadia Dac Vice President and Chief Commercial Officer
Dr. Andreas Grauer M.D. Vice President and Chief Medical Officer
David W. Ghesquiere Vice President and Chief Business Development Officer

Latest SEC Filings

Date Type Title
May 30, 2025 ARS Filing
May 30, 2025 DEF 14A Other definitive proxy statements
May 16, 2025 8-K/A [Amend] Current report
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report
May 6, 2025 8-K Current Report
Apr 30, 2025 10-K/A [Amend] Annual report
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 8-K Current Report
Feb 21, 2025 SCHEDULE 13G/A Filing